A protein for the mass production of antibodies

A protein for the mass production of antibodies
Tile-scan of a mouse spleen stained with MOMA1 (red) and CD23 (blue) and shows splenic architecture as assessed by immunohistochemical staining for the B cell marker CD23, and the metallophilic macrophage marker MOMA1 to visualize splenic marginal zones. Credit: IMBA/Hagelkruys

Antibodies play a fundamental role in medicine, and antibody-mediated immune response is the ultimate target in the quest for a vaccine to defeat the current pandemic. These minute proteins, also called immunoglobulins, are used by the body as a critical deterrent against invading pathogens. They do this by recognizing and tagging foreign substances so that they can be identified by the immune system. They also help to destroy intruders with the help of other immune cells.

JAGN1 as a player on the immune system's team

Dr. Josef Penninger's group at IMBA and at UBC, where he is the director of the Life Sciences Institute and a professor in the Department of Medical Genetics, focused on the role of a specific protein called JAGN1 in the production of antibodies. The gene JAGN1 had been previously identified as a player in the body's by the Penninger lab in collaboration with the Klein lab at LMU in Munich among patients with severe congenital neutropenia (SCN)—a disease caused by a mutation in the JAGN1 gene. Patients with SCN have abnormally low levels of white blood called neutrophils, and suffer from serious infections because their immune systems cannot effectively kill off bacterial or fungal invaders.

In the current study, the researchers shed light on the role of JAGN1 in relation to B-cells, that can develop into when they recognize foreign substances (antigens) such as chemicals, bacteria, viruses and pollen. In plasma cell form, B-cells can produce thousands of antibodies per second that target a specific antigen. This production occurs at a location within the cell known as the endoplasmic reticulum.

As a finishing touch on their production, the antibodies are "decorated" with on their Fc region, an area that interacts with other parts of the immune system. This process, called glycosylation, facilitates the antibody's ability to bind to other immune cells, thereby strengthening the body's defensive reaction. Characteristic sugar structures that are attached to proteins are known to have an impact on protein stability and communication between cells and their environment.

"When we knocked out JAGN1 in B-cells of mice, we were able to measure a drastic reduction in the number of antibodies," says Dr. Astrid Hagelkruys, Senior Research Associate at IMBA and first author of the study. "In addition, their glycosylation pattern—the addition of specific sugar molecules—was altered on antibodies of JAGN1-deficient B-cells."

"JAGN1 seems to influence the antibody factories in the cells," says Dr. Penninger. "To our surprise, this change in the sugar structure also leads to a better ability of the antibodies to bind to other immune cells and strengthens the defense reaction."

The scientists were also able to demonstrate this mechanism in human samples. "Rare genetic defects occur in only a handful of people," adds Dr. Penninger, "but they can sometimes help us decipher basic principles of biology. In this case, we were able to prove that a certain gene affects the endoplasmic reticulum and is therefore essential for the mass production of antibodies. At the same time, we also found out that the "sugar coat" of antibodies is changed, which has an important effect on how such actually work in the body."

Explore further

Declining antibodies and immunity to COVID-19 – why the worry?

More information: Astrid Hagelkruys et al. A crucial role for Jagunal homolog 1 in humoral immunity and antibody glycosylation in mice and humans, Journal of Experimental Medicine (2020). DOI: 10.1084/jem.20200559
Journal information: Journal of Experimental Medicine

Provided by Institute of Molecular Biotechnology (IMBA)
Citation: A protein for the mass production of antibodies (2020, September 16) retrieved 16 May 2022 from https://medicalxpress.com/news/2020-09-protein-mass-production-antibodies.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors